The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Open accessAbstract
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant samples. Liquid chromatography-mass spectrometry metabolite screening revealed increased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide phosphate (NADPH)–dependent reduction of α-ketoglutarate (α-KG) to 2-HG. The IDH1 R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases the affinity for NADPH and α-KG. This prevents the oxidative decarboxylation of isocitrate to α-KG, and facilitates the conversion of α-KG to 2-HG. IDH1/2 mutations confer an enzymatic gain of function that dramatically increases 2-HG in AML. This provides an explanation for the heterozygous acquisition of these mutations during tumorigenesis. 2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Gross et al, 2010
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Gross et al., 2010
In the citing paper
“AML samples with low to undetectable 2HG were subsequently sequenced and determined to be IDH1 and IDH2 wild-type”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“several samples with elevated 2HG were found to have neomorphic mutations at either IDH1 R132 or IDH2 R172 (Gross et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“Enzymatic assays and measurement of 2HG levels in primary AML samples confirmed that these IDH2 R172 mutations result in 2HG elevation (Gross et al., 2010; Ward et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
In the citing paper
“serum 2HG levels have successfully correlated with IDH1 R132 mutations in AML”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Gross et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 744
Graubert, T. A., Brunner, A. M., & Fathi, A. T. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e334 · Cited by 12
Clinical Targeting of Altered Metabolism in High-Grade Glioma
Scott, A. J., Lyssiotis, C. A., & Wahl, D. R. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000550 · Cited by 11
Pichler, M. M., Bodner, C., Fischer, C., Deutsch, A. J. A., Hiden, K., Beham‐Schmid, C., Linkesch, W., Guelly, C., Sill, H., & Wölfler, A. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08404.x · Cited by 11
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
Yao, Y. (2014) · Medical Science Monitor · doi:10.12659/msm.889891 · Cited by 11
Chen, X., Wu, X., Gao, J., Ying, H., Dong, X., Che, J., & Shen, Z. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000063 · Cited by 12
Gregorio, E. D., Miolo, G., Saorin, A., Steffan, A., & Corona, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115574 · Cited by 11
Jin, M., Wang, P., Li, X., Zhao, X., Xu, L., Song, P., & Zhu, G. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2371-8 · Cited by 11
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 11
Withanolides from dietary tomatillo suppress HT1080 cancer cell growth by targeting mutant IDH1
Yang, Y., Xiang, K., Sun, D., Zheng, M., Song, Z., Li, M., Wang, X., Li, H., & Chen, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116095 · Cited by 11
Replenishment of TCA cycle intermediates and long-noncoding RNAs regulation in breast cancer
Zheng, X., Zhang, S., Ma, H., Dong, Y., Zheng, J., Zeng, L., Liu, J., Dai, Y., & Yin, Q. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112321 · Cited by 10
Advancing Systemic Therapy in Chondrosarcoma: New Horizons
Li, K. H. C., Gulia, A., Duffaud, F., & Jones, R. L. (2024) · Oncology and Therapy · doi:10.1007/s40487-024-00317-z · Cited by 10
Cortes, J. E., Yang, J., Roboz, G. J., Dinner, S. N., Wang, E. S., Wei, A. H., Tian, H., Trapani, F. D., Baer, M. R., Donnellan, W. B., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016718 · Cited by 10
A Förster resonance energy transfer-based d-2-hydroxyglutarate biosensor
Xiao, D., Xu, X., Gao, K., Wang, M., Zhang, W., Lü, C., Wang, X., Wang, Q., Xu, P., Ma, C., et al. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133681 · Cited by 10
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor
Liang, Q., Wang, B., Zou, F., Guo, G., Wang, W., Wang, W., Liu, Q., Shen, L., Hu, C., Wang, W., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115411 · Cited by 10
HDAC6 deacetylates IDH1 to promote the homeostasis of hematopoietic stem and progenitor cells
Yang, J., Liu, Y., Yin, H., Xie, S., Zhang, L., Dong, X., Ni, H., Bu, W., Ma, H., Liu, P., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256009 · Cited by 10
CHAO, H. ‐., Jia, Z., Chen, T., LU, X. ‐., CEN, L., XIAO, R., JIANG, N. ‐., Ying, J., Zhou, M., & Zhang, R. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01422.x · Cited by 10
The Frequency and Clinical Significance of IDH1 Mutations in Chinese Acute Myeloid Leukemia Patients
Guan, L., Gao, L., Wang, L., Li, M., Yin, Y., Li, Y., & Gao, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083334 · Cited by 10
Hu, Y., Gao, A., Liao, H., Zhang, M., Xu, G., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., et al. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800039 · Cited by 10
Che, J., Huang, F., Zhang, M., Xu, G., Qu, B., Gao, J., Chen, B., Zhang, J., Ying, H., Hu, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112491 · Cited by 10
Idle, J. R., Seipel, K., Bacher, U., Pabst, T., & Beyoğlu, D. (2020) · Cancers · doi:10.3390/cancers12102842 · Cited by 10
Tong, J., Bian, S., Zhang, X., & Luo, D. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10222-6 · Cited by 10
Peng, S., Chen, H., Chen, L., Yang, G., Liu, J., Cheng, X., & Tang, Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00254 · Cited by 10
Miyata, S., Urabe, M., Gomi, A., Nagai, M., Yamaguchi, T., Tsukahara, T., Mizukami, H., Kume, A., Ozawa, K., & Watanabe, E. (2013) · Neurologia medico-chirurgica · doi:10.2176/nmc.oa2012-0409 · Cited by 10
Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid
Jones, P. M., Boriack, R. L., Struys, E. A., & Rakheja, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8_14 · Cited by 10
The Molecular Basis of Histone Demethylation
Horton, J. R., Gale, M., Yan, Q., & Cheng, X. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_7 · Cited by 10
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability
Kingsbury, J. M., Shamaprasad, N., Billmyre, R. B., Heitman, J., & Cardenas, M. E. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw195 · Cited by 10
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 9
CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia
Lyu, J., Liu, Y., Liu, N., Vu, H. S., Cai, F., Cao, H., Kaphle, P., Wu, Z., Botten, G. A., Zhang, Y., et al. (2025) · Blood · doi:10.1182/blood.2024027207 · Cited by 10
Rakheja, D., Fuda, F. S., Vandergriff, T. W., Boriack, R. L., Medeiros, B. C., Frankel, A. E., & Chen, W. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.10.013 · Cited by 9
Li, F., Yue, C., Deng, Y., & Tang, Y. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315033 · Cited by 9
Li, Y., Connarn, J. N., Chen, J., Tong, Z., Palmisano, M., & Zhou, S. Y. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s192687 · Cited by 9
Asensio, A. F., Álvarez-González, E., Rodríguez, A., Sierra, L. M., & Blanco‐González, E. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338646 · Cited by 10
Zhang, B., Wang, P., Wang, A., Wang, W., Tang, W., & Zhu, G. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2210-y · Cited by 9
The role of NAD+-dependent isocitrate dehydrogenase 3 subunit α in AFB1 induced liver lesion
Yang, C., Fan, J., Zhuang, Z., Fang, Y., Zhang, Y., & Wang, S. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.10.037 · Cited by 9
Richard‐Carpentier, G., Gupta, G., Koraksic, C., Cathelin, S., Wang, L. E., Bankar, A., Davidson, M. B., Gupta, V. K., Maze, D. C., Minden, M. D., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00254-6 · Cited by 8
Self-citationRole of Additional Novel Therapies in Myeloproliferative Neoplasms
Fiskus, W. C., Ganguly, S., Kambhampati, S., & Bhalla, K. N. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.001 · Cited by 8
Oncometabolites as Regulators of DNA Damage Response and Repair
Gueble, S. E., & Bindra, R. S. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.09.004 · Cited by 8
Epigenetic Mechanisms in Hematologic Aging and Premalignant Conditions
Yan, B., Yuan, Q., & Guryanova, O. A. (2023) · Epigenomes · doi:10.3390/epigenomes7040032 · Cited by 8
A perioperative study of Safusidenib in patients with IDH1 -mutated glioma
Cain, S. A., Topp, M. D., Rosenthal, M. A., Tobler, R., Freytag, S., Best, S. A., Whittle, J. R., & Drummond, K. J. (2024) · Future Oncology · doi:10.1080/14796694.2024.2383064 · Cited by 9
AML Genomics for the Clinician
Graubert, T. A., & Stone, R. M. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.006 · Cited by 8
Zhang, J., Hu, L., Wang, H., Zhi, J., Hou, X., Wu, Y. H., Zheng, X., & Gao, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194920 · Cited by 8
Adilijiang, A., Hirano, M., Okuno, Y., Aoki, K., Ohka, F., Maeda, S., Tanahashi, K., Motomura, K., Shimizu, H., Yamaguchi, J., et al. (2019) · Molecules · doi:10.3390/molecules24173046 · Cited by 8
Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective
Thamim, M., & Thirumoorthy, K. (2020) · European Biophysics Journal · doi:10.1007/s00249-020-01460-x · Cited by 8
Kobayashi, M., Abe, H., Arai, K., Murakami, S., & Kamai, T. (2022) · Current Urology · doi:10.1097/cu9.0000000000000091 · Cited by 8
Song, P., Wei, H., Cao, Z., Wang, P., & Zhu, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115025 · Cited by 8
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Wu, F., Cheng, G., Yao, Y., Kogiso, M., Jiang, H., Li, X., & Song, Y. (2018) · Medicinal Chemistry · doi:10.2174/1573406414666180524093659 · Cited by 8
Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers
Raynaud, S., Carbuccia, N., Colin, C., Adélaı̈de, J., Mozziconacci, J., Métellus, P., Chinot, O. L., Birnbaum, D., Chaffanet, M., & Figarella-Branger, D. F. (2010) · Oncology Letters · doi:10.3892/ol_00000156 · Cited by 8
Yao, K., Liu, P., Liu, H., Wei, Q., Yang, J., Cao, P., & Lai, Y. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.03.092 · Cited by 8
Zuo, Z., Li, S., Xu, J., You, M. J., Khoury, J. D., & Yin, C. C. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00534-8 · Cited by 8
Challenges of Spatially Resolved Metabolism in Cancer Research
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2024) · Metabolites · doi:10.3390/metabo14070383 · Cited by 8
Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs
Cheng, H., Li, Z., Guo, Z., Shao, S., Mo, L., Wei, W., & Xue, M. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113368 · Cited by 7
Kalushkova, A., Nylund, P., Párraga, A. A., Lennartsson, A., & Jernberg‐Wiklund, H. (2021) · Epigenomes · doi:10.3390/epigenomes5040022 · Cited by 7
Natsumeda, M., Igarashi, H., Gabdulkhaev, R., Takahashi, H., Motohashi, K., Ogura, R., Watanabe, J., Tsukamoto, Y., Okamoto, K., Kakita, A., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11112129 · Cited by 7
Resolving Enantiomers of 2-Hydroxy Acids by Nuclear Magnetic Resonance
Lin, P., Crooks, D. R., Linehan, W. M., Fan, T. W. ‐., & Lane, A. N. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00490 · Cited by 7
Ježíšková, I., Rázga, F., Bajerová, M., Ráčil, Z., Mayer, J., & Dvořáková, D. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.523126 · Cited by 7
Magnetic Resonance Metabolic Imaging of Glioma
Métellus, P., & Figarella-Branger, D. F. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003591 · Cited by 7
Wang, Z., Chang, Y., Han, Y., Liu, K.-J., Hou, J., Dai, C., Zhai, Y., Guo, J., Sun, P., Lin, J., et al. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.06.044 · Cited by 7
malignancy, A. I. A. H. H., mutations, C. B. T. A. O. V. S. G. A. A. O. I. M. C. A. A. V. S. O. M. S. C. O. I. T. L. 2. D. H. L. T. T. I. O. T. B. T. O. G., (HPCs), W. C. T. S. D. O. T. L. P. T. C. I. M. C. A. S. A. T. H. S. C. (. A. P. C., in, S. A. T. M., of, T. L., in, O. T. M., HPCs, R. T. K. T. C. I. M. P. S.-R. A. B. T. D. O., involving, S. A. T. T. F., & involving, O. T. T. F. (2016) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2016.00019 · Cited by 8
Miyake, K., Baba, Y., Ishimoto, T., Hiyoshi, Y., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., Ogata, Y., Nagayama, M., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1229-x · Cited by 7
Yeh, L.-C., Shyu, H.-W., Jin, Y.-R., Chiou, Y., Lin, K., Chou, M.-C., Huang, M., & Wang, Y. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.104753 · Cited by 7
Modrzejewska, M., Gawroński, M., & Gackowski, D. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114129 · Cited by 7
Fortina, P., Londin, E., Park, J. Y., & Kricka, L. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8 · Cited by 7
Rakheja, D., Khokhar, S., Mitui, M., & Cost, N. G. (2012) · Pediatric and Developmental Pathology · doi:10.2350/12-01-1151-oa.1 · Cited by 7
Abiria, S. A., Williams, T. V., Munden, A. L., Grover, V. K., Wallace, A., Lundberg, C. J., Valadez, J. G., & Cooper, M. K. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1481-7 · Cited by 7
Shea, A., Risio, L. D., Carruthers, H., Ekiri, A. B., & Beltrán, E. (2016) · Veterinary Record · doi:10.1136/vr.103783 · Cited by 7
Prognostic and predictive markers in glioblastoma and ALK overexpression
Kim, J. (2021) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2021.04.29 · Cited by 7
Parry, A., Krueger, C., Lohoff, T., Wingett, S., Schoenfelder, S., & Reik, W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523441 · Cited by 7
Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
Taborda, C., Zeidan, A. M., & Mendez, L. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1419323 · Cited by 6
Afsari, F., & McIntyre, T. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200050 · Cited by 6
Mass spectrometry in leukemia research and treatment
Roboz, J., & Roboz, G. J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1018889 · Cited by 6
Pessôa, I. A., Sagica, F. D. E. S., Anselmo, N. P., Brito, J. R. N., & de Oliveira, E. H. C. (2015) · Genetics and Molecular Research · doi:10.4238/2015.june.12.6 · Cited by 6
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML
Kingsley, M. C., Xie, H. M., Chen, B.-R., Riedel, S. S., Pastuer, T., Bollig, M. K., Shank, T., Libbrecht, C., Stabler, S. P., Deshpande, A. J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001922 · Cited by 6
Agopian, J., Costa, Q. D., Nguyen, Q. V., Scorrano, G., Kousteridou, P., Yuan, M., Chelbi, R., Goubard, A., Castellano, R., Maurizio, J., et al. (2021) · Blood · doi:10.1182/blood.2020008948 · Cited by 6
Pan, Y., Yan, C., Hu, Y., Fan, Y., Pan, Q., Wan, Q., Torcivia-Rodriguez, J., & Mazumder, R. (2017) · Scientific Reports · doi:10.1038/srep42169 · Cited by 6
Krämer, A., & Bochtler, T. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_9 · Cited by 6
Brain multi-omic Mendelian randomisation to identify novel drug targets for gliomagenesis
Thornton, Z. A., Andrews, L., Zhao, H., Zheng, J., Paternoster, L., Robinson, J. W., & Kurian, K. M. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae168 · Cited by 6
Ohtawa, T., Hattori, A., Isokawa, M., Harada, M., Funatsu, T., Ito, T., & Tsunoda, M. (2021) · Journal of Chromatography Open · doi:10.1016/j.jcoa.2021.100005 · Cited by 5
R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes
Kawakami, S., Ochiai, K., Azakami, D., Kato, Y., Michishita, M., Morimatsu, M., Ishiguro‐Oonuma, T., Onozawa, E., Watanabe, M., & Omi, T. (2017) · Veterinary Research Communications · doi:10.1007/s11259-017-9707-8 · Cited by 5
Bories, P.-N., Nakib, S., Cynober, L., Alary, A., Coudé, M.-M., Chevillon, F., Tamburini, J., Birsen, R., Kosmider, O., & Bouscary, D. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0427 · Cited by 5
Arceci, R. J., Berman, J. N., & Meshinchi, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00017-7 · Cited by 5
Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate
Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 5
Anomalies génétiques et moléculaires des glioblastomes (GBM)
Larsen, C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1215 · Cited by 5
Cancer Therapies Targeting Cellular MetabolismPreprint
Morris, B. L., & Gutiérrez, A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041657 · Cited by 5
Metabolic instruction of the graft-versus-leukemia immunity
Burk, A., & Apostolova, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347492 · Cited by 4
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
Fang, Y., Wang, X., Luo, K., Dakal, T. C., Bai, H., Xu, C., & Zhang, G. (2026) · MedComm · doi:10.1002/mco2.70732 · Cited by 5
Zhang, C., Chu, A., Boriack, R. L., Collins, R. H., Xu, J., Oliver, D., Zheng, R., Rakheja, D., & Chen, W. (2023) · eJHaem · doi:10.1002/jha2.723 · Cited by 4
Screening forIDHmutations in chronic myelomonocytic leukemia
Ibáñez, M., Such, E., Cervera, J., Luna, I., Gómez‐Seguí, I., López‐Pavía, M., Avaría, A., Senent, M. L., Sanz, G. F., & Sanz, M. Á. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.701295 · Cited by 4
Song, P., Li, S., Wu, Y., Lv, C., Wang, P., & Zhu, G. (2016) · Journal of Basic Microbiology · doi:10.1002/jobm.201600096 · Cited by 4
Ho, C., & Kluk, M. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.011 · Cited by 4
From a dimer to a monomer: Construction of a chimeric monomeric isocitrate dehydrogenase
Tian, C., Wen, B., Bian, M., Jin, M., Wang, P., Xu, L., & Zhu, G. (2021) · Protein Science · doi:10.1002/pro.4204 · Cited by 4
IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders (Review)
Ya, G., Wei, S., Wei, Y., Chen, Y., Cui, J. T., Yu, Y., Lin, X., Yan, H., Qin, H., & Yi, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13398 · Cited by 4
Lai, C., Leahy, T. P., Turner, A. J., Thomassen, A., Wang, L., Sheppard, A. D., & Cortes, J. E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2514894 · Cited by 4
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4
Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies
Jankowska, A. M., & Szpurka, H. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.006 · Cited by 4
Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet
Bhagwat, N., & Levine, R. L. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001669 · Cited by 4
Ali, M. A. M., Ahmed, E. K., Assem, M., & Helwa, R. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0852-6 · Cited by 4
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells
Hu, L., Lin, J., Sun, L., Berezuk, A., Tuttle, K. S., Zhu, X. Q., Seo, H., Dhe‐Paganon, S., Li, P., Sun, Y., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02131-8 · Cited by 3
Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias
Laister, R. C., Minden, M. D., & Mak, T. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_38 · Cited by 3
Self-citationMetabolic basis of cardiac dysfunction in cancer patients
Figueiredo, J. C., Bhowmick, N. A., & Karlstaedt, A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001118 · Cited by 3
Clinical and imaging characteristics of supratentorial glioma with IDH2 mutation
Ikeda, S., Sakata, A., Arakawa, Y., Mineharu, Y., Makino, Y., Takeuchi, Y., Fushimi, Y., Okuchi, S., Nakajima, S., Otani, S., et al. (2024) · Neuroradiology · doi:10.1007/s00234-024-03361-8 · Cited by 3
Metadata
- Authors
- Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., Dang, L., Fantin, V. R., & Mak, T. W.
- Affiliations
- Agios Pharmaceuticals Incorporated, Cambridge, MA 02139 1
- University Health Network (CA)
- Agios Pharmaceuticals (United States) (US)
- Corresponding author
- Fantin, Valeria R.
- Mak, Tak W.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-02-08
- Volume
- 207
- Issue
- 2
- Pages
- 339-344
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2822606
- OpenAlex
- W2159731673
- Cited by
- 736
- References
- 23
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 34 · 2023: 35 · 2022: 29 · 2021: 55 · 2020: 40 · 2019: 36 · 2018: 45 · 2017: 51 · 2016: 61 · 2015: 44 · 2014: 49 · 2013: 61 · 2012: 61
- FWCI
- 45.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- Agios Pharmaceuticals
- Terry Fox Foundation
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, IDH mutation, acute myeloid leukemia, alpha-ketoglutarate, NADPH-dependent reduction, gain-of-function mutations, cancer metabolism, metabolic biomarkers
- MeSH terms
- Catalysis, Glutarates, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Mutation, NADP, Recombinant Proteins, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
